Diageo plc Strong consistent performance

Diageo Plc

• Reported net sales (£12.9 billion) increased 5.8% with organic growth partially offset by acquisitions and disposals. Reported operating profit (£4.0 billion) increased 9.5%, driven by organic growth

• All regions contributed to broad based organic net sales growth, up 6.1%, with organic volume up 2.3%

• Organic operating profit grew 9.0%, ahead of top line organic growth, driven by improved price/mix and productivity benefits from everyday cost efficiencies, partially offset by cost inflation and higher marketing investment

• Cash flow continued to be strong, with net cash from operating activities at £3.2 billion, up £164 million and free cash flow at £2.6 billion, up £85 million

• Basic eps of 130.7 pence increased by 7.4%. Pre-exceptional eps grew 10.3% to 130.8 pence, driven by higher operating profit and lower finance charges, which more than offset an increased tax charge as a result of higher profit

• On 25 July the Board approved plans for a further return of capital up to £4.5 billion to shareholders for the period F20 to F22.

• The final dividend increased 5% bringing the full year dividend to 68.57 pence per share

See Explanatory notes for explanation and reconciliation of non-GAAP measures.

Ivan Menezes, Chief Executive, commenting on the results said:

“Diageo has delivered another year of strong performance. Organic volume and net sales growth was broad based across regions and categories, with new product innovation being a strong contributor. We expanded organic operating margin ahead of our guidance and increased investment behind our brands ahead of organic net sales growth.

Fiscal 19 has been another year of strong free cash flow delivery at £2.6 billion and we have returned £2.8 billion to shareholders via share buybacks. The Board has approved plans for an additional return to shareholders of up to £4.5 billion over Fiscal 20 to Fiscal 22.

Our focus on quality sustainable growth is backed by a culture of everyday efficiency that enables us to invest smartly in marketing and growth initiatives while expanding margins.

These results reflect the steady progress we are making and as we look ahead we see attractive opportunities to deliver consistent growth and create shareholder value. In the medium term I expect Diageo to maintain organic net sales growth in the mid-single digit range and to grow organic operating profit ahead of net sales in the range of 5%-7%.” 

Share on:
Find more news, interviews, share price & company profile here for:

    Global Opportunities Trust reports 11.9% one year share price return to 31 August

    Global Opportunities Trust has released its August 2025 factsheet, reporting a 12-month NAV increase of 8.8% and a share price gain of 11.8%.

    Dekel Agri-Vision reports 24.5% revenue growth and break-even net profit in H1 2025

    Dekel Agri-Vision posted a stronger performance for the six months ended 30 June 2025, with Group revenue up 24.5% to €23.9m and EBITDA rising 10.7% to €3.1m.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Quadrise signs addendum with Valkor to re-phase payments and MMU deliveries

    Quadrise has agreed an addendum to its Site License and Supply Agreement with Valkor Technologies in Utah. The revised terms re-phase the US$1.0 million licence fee through to June 2026 and adjust delivery schedules for Multifuel Manufacturing Units.

    Ampeak Energy reports interim results and financial close of first battery project

    Ampeak Energy has published its unaudited interim results for the six months ended 30 June 2025. The Group focused on achieving financial close of the 240 MWh AW1 battery project at Uskmouth, which was completed in August 2025.

    Nuformix to present NXP002 data at ERS Congress 2025

    Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis.

      Search

      Search